Disruption Labs’ Formal Seed Round Over-Subscribed

AUSTIN, Texas, Feb. 26, 2020 /PRNewswire/ — Disruption Labs, Inc. (parent company to Santé Laboratories LLC & RESET Bioscience LLC) is pleased to announce that it has closed its Seed Round investment oversubscribed at $3,800,000 via the sale of common stock. The Seed Round was led by Andrew Garnock / ARJ Consulting, LLC.

“Andrew shares our vision in the future of hemp compliance” said Disruption CEO Chris Barber, “as we move from R&D to the commercialization of our proprietary nano delivery platform, we plan to be the market leading advanced cannabinoid supplier. With our shelf stable, highly bioavailable, customizable products we enable brands to future proof for regulation, without paying a premium to the current CBD oil ‘one size fits all’ market”.

“While I believe that branding will play strongly in the THC cannabis market, this is my only hemp CBD investment, as I think it will be the science and technology that will drive this market. I think Disruption Labs is well positioned to be a leading manufacturer with its proprietary IP nano delivery platform” said Andrew Garnock.

The funds will help the scale up bulk manufacturing capacity of Santé Labs as well as working capital to further build out the team. Santé Labs, the first ISO hemp testing lab in Texas, is also expanding its hemp services and scaling up with Texas, and adjacent states, hemp farming demands.

“We are razor focused on the future of cannabinoid products and services. Our platform can encapsulate cannabinoids in a cost effective, validated, consistent and stable manner that is critical for a future regulated hemp products market. We have user cases for applications in heat for food, in beverages, in shelf stable tinctures, capsules and effervescent powders.” said Matt Reid, Disruption President.

About Disruption Labs, Inc.  

Background

Founded November 2017 Disruptions Labs is the parent company of Santé Labs and RESET Bioscience. Santé is built to service the rapid growing global cannabinoid industry with advanced manufacturing and a deep focus on Texas for farming analytics. Santé’s nano-encapsulated ingredient technology; meets future regulatory rigor and label compliance, offers meaningful product differentiation and is price competitive with the current crude oil market. Through proprietary analytics, Santé Labs is leading innovation in the testing space by providing the industry the ability to evaluate if products meet shelf-life stability and label claim for potency and particle size. Santé is focused on generating legally defensible & scientifically valid data packages to support stakeholders with assurance on superior stability & maximum shelf life. RESET Bioscience is a fast-growing advanced CBD brand with distribution into EU and Asian markets (www.resetbioscience.com).  

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results to differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made

Contact:

Chris Barberchris.barber@disruption-labs.com

SOURCE Disruption Labs

Leave a Reply